Paolo Vigneri
Overview
Explore the profile of Paolo Vigneri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
2800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stagno F, Stella S, Leotta S, Caserta S, Vitale S, Markovic U, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076467
Hydroxyurea (HU) cytoreduction is usually administered to patients with chronic myeloid leukemia before starting any tyrosine kinase inhibitors (TKIs) therapy. However, up to date, there is no evidence of any...
2.
Motta L, Puglisi M, Pavone G, Motta G, Martorana F, Bambaci M, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941824
Background: In recent years, the role of prostate-specific membrane antigen (PSMA) in the imaging and treatment of prostate cancer (PCa) has been extensively investigated. However, despite its name, PSMA is...
3.
Massimino M, Tirro E, Stella S, Tomarchio C, Di Bella S, Vitale S, et al.
Biomolecules
. 2025 Jan;
15(1).
PMID: 39858540
Background: Despite advances in uveal melanoma (UM) diagnosis and treatment, about 50% of patients develop distant metastases, thereby displaying poor overall survival. Molecular profiling has identified several genetic alterations that...
4.
Schettini F, Nucera S, Pascual T, Martinez-Saez O, Sanchez-Bayona R, Conte B, et al.
Cancer Treat Rev
. 2024 Dec;
132:102865.
PMID: 39709655
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low...
5.
Conti C, Nucera S, Di Grazia G, Martorana F, Motta F, Vigneri P, et al.
Case Rep Oncol
. 2024 Dec;
17(1):1358-1365.
PMID: 39640070
Introduction: Managing uncommon metastatic sites from different solid tumors is challenging since no available guidelines define the best therapeutic approaches for these rare clinical events. Thus, malignancies giving rise to...
6.
Pavone G, Marino A, Fisicaro V, Motta L, Spata A, Martorana F, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408687
Cervical cancer (CC) remains a prevalent malignancy and a significant global public health concern, primarily driven by persistent human papillomavirus (HPV) infections. The infectious nature of HPV underscores the preventability...
7.
Gentile D, Martorana F, Karakatsanis A, Caruso F, Caruso M, Castiglione G, et al.
Eur J Surg Oncol
. 2024 Oct;
50(12):108732.
PMID: 39362047
Introduction: Neoadjuvant therapy (NAT) should increase the rate of breast-conserving surgery (BCS) in non-metastatic breast cancer (BC) patients, especially in those achieving tumor shrinkage. Still, the conversion from a pre-planned...
8.
Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S, et al.
Front Oncol
. 2024 Aug;
14:1427228.
PMID: 39211557
The REarranged during Transfection (RET) receptor tyrosine kinase plays a crucial role in the development of various anatomical structures during embryogenesis and it is involved in many physiological cellular processes....
9.
Schettini F, Gattazzo F, Nucera S, Rubio Garcia E, Lopez-Aladid R, Morelli L, et al.
Cancer Treat Rev
. 2024 Aug;
130:102816.
PMID: 39182440
The human body represents the habitat of trillions of symbiotic microorganisms, collectively known as human microbiota, approximately half of which residing in the gut. The development of next-generation sequencing techniques...
10.
Helmijr J, Motta G, Jongbloed L, de Weerd V, van Bergen L, Verschoor N, et al.
J Appl Lab Med
. 2024 Jul;
9(5):913-925.
PMID: 39012846
Background: Activating mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene have been detected often in solid tumors. Targeted therapy for mutant PIK3CA is now available in the clinic,...